Tulavi Therapeutics, Inc. — Form D
Tulavi Therapeutics, Inc. of MOUNTAIN VIEW, CA, a company, filed a Form D exempt-offering notice with the SEC on 2018-04-30. The offering totals $3.0M, of which $1.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-04-30
- Form: D
- Accession: 0001738995-18-000001
- Industry: Biotechnology
- Exemptions: 06c
- Total offering: $3.0M
- Amount sold: $1.8M
- Remaining: $1.2M
- Minimum investment: $160K
- Investors: 1
- Date of first sale: 2018-04-24
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-311235
Issuer
- Name: Tulavi Therapeutics, Inc.
- CIK: 0001738995
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 1928 OLD MIDDLEFIELD WAY, SUITE B, MOUNTAIN VIEW, CA, 94043
- Phone: 650-248-7914
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Henry Chen | Director | BEDFORD, MA |
| Tara Butler | Director | BEDFORD, MA |
| Farhad Khosravi | Director | BEDFORD, MA |
| Farhad Khosravi | Executive Officer | BEDFORD, MA |
| Greg Casciaro | Director | Salt Lake City, UT |
| Corinne Bright | Director | Mountain View, CA |
| Corinne Bright | Executive Officer | Mountain View, CA |
| Amar Sawhney | Director | Mountain View, CA |
| Steve Willamson | Director | Mountain View, CA |
| Amar Sawney | Director | Mountain View, CA |
Other filings by this issuer (4)
More